Genes Tech Group Holdings Company Limited

As of December 31, 2023, Genes Tech Group Holdings Company Limited has 1.00B shares outstanding.

As of December 31, 2023, Genes Tech Group Holdings Company Limited trades at a trailing price-to-earnings ratio of 2.95. The price-to-sales ratio is 0.20, and the price-to-book ratio stands at 0.79.

As of December 31, 2023, Genes Tech Group Holdings Company Limited trades at an EV/EBITDA multiple of 5.39 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.56 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 5.39 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Genes Tech Group Holdings Company Limited trades at an EV/FCF ratio of 53.48, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of December 31, 2023, Genes Tech Group Holdings Company Limited maintains a current ratio of 1.46, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 78.89, indicating elevated leverage, while an interest coverage ratio of 7.12 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended December 31, 2023, Genes Tech Group Holdings Company Limited posted a return on equity (ROE) of 30.05, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.95 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.95, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 10.90, useful for judging operating efficiency across full business cycles. Inventory turnover of 0.86 indicates how many times Genes Tech Group Holdings Company Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures cover the twelve months ended December 31, 2023. That works out to an effective tax rate of 28.23, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

As of the close on March 4, 2026, Genes Tech Group Holdings Company Limited's stock has gained approximately 238.89% over the past 52 weeks. The 50-day moving average sits at 0.24, while the 200-day moving average is 0.13.

Over the twelve months ended December 31, 2023, Genes Tech Group Holdings Company Limited posted a gross margin of 24.46, reflecting its pricing power and cost economics. The operating margin of 10.46 and net profit margin of 6.80 provide insight into operational efficiency.

As of December 31, 2023, Genes Tech Group Holdings Company Limited has an Altman Z-Score of 1.53, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.